Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension - Top-Institutions - MDSpire

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • By

  • WenXia Li

  • RuRan Li

  • ShanShan Li

  • Zhen Li

  • JingSu Ma

  • Fei Wu

  • ChaoQin Chen

  • May 11, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Danzhou People’s Hospital
    Danzhou People’s Hospital

    Danzhou, Hainan

    Key Differentiators

    • Endocrinology

  • #2

    Hainan Medical University
    Hainan Medical University

    Haikou, Hainan

    Key Differentiators

    • Endocrinology

Original Source(s)

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • by WenXia Li, RuRan Li, ShanShan Li, Zhen Li, JingSu Ma, Fei Wu, ChaoQin Chen

  • May 11, 2026

Related Content

Association of sleep variability and irregularity with gestational metabolic syndrome: a birth cohort study

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Machine Learning Prediction Model for Dyslipidemia and Its Association With Atherothrombotic Events in 3 Independent Cohorts From South Korea, Japan, and the United Kingdom: Algorithm Development and Validation Study